Chongqing Pharscin Pharmaceutical Co., Ltd.
Shenzhen Stock ExchangeTotal Valuation
Chongqing Pharscin Pharmaceutical Co., Ltd. carries a market capitalization of 5.53B, placing it among publicly traded companies globally. Its enterprise value stands at 6.49B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 5.53B |
| Enterprise Value | 6.49B |
Share Statistics
Chongqing Pharscin Pharmaceutical Co., Ltd. currently has 417.60M shares outstanding.
| Shares Outstanding | 417.60M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Chongqing Pharscin Pharmaceutical Co., Ltd. trades at a trailing price-to-earnings ratio of 83.34. The price-to-sales ratio is 8.71, and the price-to-book ratio stands at 6.14.
| PE Ratio | 83.34 |
| PS Ratio | 8.71 |
| PB Ratio | 6.14 |
| P/TBV Ratio | 4.76 |
| P/FCF Ratio | 527.62 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Chongqing Pharscin Pharmaceutical Co., Ltd. trades at an EV/EBITDA multiple of 76.32 and an EV/FCF ratio of 507.59. The EV/Sales ratio of 8.13 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 76.32 provides insight into valuation relative to core operating earnings.
| EV / Sales | 8.13 |
| EV / EBITDA | 76.32 |
| EV / EBIT | 76.32 |
| EV / FCF | 507.59 |
Financial Position
Chongqing Pharscin Pharmaceutical Co., Ltd. maintains a current ratio of 4.24, meaning it holds 4.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.24, indicating elevated leverage, while an interest coverage ratio of -180.29 demonstrates limited ability to service its debt obligations.
| Current Ratio | 4.24 |
| Quick Ratio | 2.05 |
| Debt / Equity | 2.24 |
| Debt / EBITDA | 0.45 |
| Interest Coverage | -180.29 |
Financial Efficiency
Chongqing Pharscin Pharmaceutical Co., Ltd. posts a return on equity of 7.50 and a return on invested capital of 4.17.
| Return on Equity (ROE) | 7.50 |
| Return on Assets (ROA) | 4.28 |
| Return on Invested Capital (ROIC) | 4.17 |
| Return on Capital Employed (ROCE) | 7.26 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.63 |
Taxes
Over the trailing twelve months, Chongqing Pharscin Pharmaceutical Co., Ltd. has paid 16.56M in income taxes, reflecting an effective tax rate of 16.84.
| Income Tax | 16.56M |
| Effective Tax Rate | 16.84 |
Stock Price Statistics
Chongqing Pharscin Pharmaceutical Co., Ltd.'s stock has declined approximately -20.33694% over the past 52 weeks. The 50-day moving average sits at 13.02, while the 200-day moving average is 14.71.
| Beta (5Y) | N/A |
| 52-Week Price Change | -20.33694% |
| 50-Day Moving Average | 13.02 |
| 200-Day Moving Average | 14.71 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Chongqing Pharscin Pharmaceutical Co., Ltd. generated 798.88M in revenue and converted that into 83.47M in net income, yielding earnings per share of 0.20. EBITDA reached 85.07M, while operating income came in at 85.07M.
| Revenue | 798.88M |
| Gross Profit | 461.45M |
| Operating Income | 85.07M |
| Pretax Income | 98.36M |
| Net Income | 83.47M |
| EBITDA | 85.07M |
| EBIT | 85.07M |
| Earnings Per Share (EPS) | 0.20 |
Balance Sheet
Chongqing Pharscin Pharmaceutical Co., Ltd. holds 525.54M in cash and equivalents against 38.29M in total debt, resulting in a net debt position of -284.55M. Total book value stands at 1.13B, with working capital of 832.02M providing operational flexibility.
| Cash & Cash Equivalents | 525.54M |
| Total Debt | 38.29M |
| Net Debt | -284.55M |
| Equity (Book Value) | 1.13B |
| Book Value Per Share | 2.71 |
| Working Capital | 832.02M |
Cash Flow
After subtracting -13.18M in capital expenditures, free cash flow totaled -13.18M - equivalent to -0.03 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -13.18M |
| Free Cash Flow | -13.18M |
| FCF Per Share | -0.03 |
Margins
Chongqing Pharscin Pharmaceutical Co., Ltd. operates with a gross margin of 57.76, reflecting its pricing power and cost economics. The operating margin of 10.65 and net profit margin of 10.45 provide insight into operational efficiency.
| Gross Margin | 57.76 |
| Operating Margin | 10.65 |
| Pretax Margin | 12.31 |
| Profit Margin | 10.45 |
| EBITDA Margin | 10.65 |
Dividends & Yields
The company's payout ratio of 17.87 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.03 |
| Dividend Yield | N/A |
| Payout Ratio | 17.87 |
| Shareholder Yield | 0.60 |
| FCF Yield | 0.19 |
Scores
Chongqing Pharscin Pharmaceutical Co., Ltd. posts an Altman Z-Score of 15.12, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 15.12 |